The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma

Experimental Cell Research

Volumn 318, Issue 14, 2012, Pages 1685-1698

  Zhou, Hua ^a   Yang, Ying Hua ^a   Binmadi, Nada O ^a,b   Proia, Patrizia ^a,c   Basile, John R ^a,d  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Angiogenesis; HIF; Oral squamous cell carcinoma; Plexin B1; Semaphorin 4D; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1BETA; KI 67 ANTIGEN; LENTIVIRUS VECTOR; PROTEIN ANTIBODY; SEMAPHORIN; SEMAPHORIN 4D; SEMAPHORIN 4D ANTIBODY; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VX 15;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR PROMOTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84862850947     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.019     Document Type: Article

References (41)

1. Mao L., Hong W.K., Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 2004, 5:311-316.
2. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 2001, 22:201-207.
3. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 1993, 268:21513-21518.
4. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19:4298-4309.
5. Uehara M., Sano K., Ikeda H., Nonaka M., Asahina I. Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol. 2009, 45:241-246.
6. Lin P.Y., Yu C.H., Wang J.T., Chen H.H., Cheng S.J., Kuo M.Y., Chiang C.P. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J. Oral Pathol. Med. 2008, 37:18-25.
7. Liu S.Y., Chang L.C., Pan L.F., Hung Y.J., Lee C.H., Shieh Y.S. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol. 2008, 44:277-285.
8. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., Semenza G.L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61:2911-2916.
9. Neufeld G., Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 2008, 8:632-645.
10. Kumanogoh A., Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001, 22:670-676.
11. Hall K.T., Boumsell L., Schultze J.L., Boussiotis V.A., Dorfman D.M., Cardoso A.A., Bensussan A., Nadler L.M., Freeman G.J. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc. Natl. Acad. Sci. USA 1996, 93:11780-11785.
12. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., Bussolino F., Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105:4321-4329.
13. Basile J.R., Barac A., Zhu T., Guan K.L., Gutkind J.S. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 2004, 64:5212-5224.
14. Basile J.R., Castilho R.M., Williams V.P., Gutkind J.S. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. PNAS 2006, 103:9017-9022.
15. Terman J.R., Mao T., Pasterkamp R.J., Yu H.H., Kolodkin A.L. MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 2002, 109:887-900.
16. Siebold C., Berrow N., Walter T.S., Harlos K., Owens R.J., Stuart D.I., Terman J.R., Kolodkin A.L., Pasterkamp R.J., Jones E.Y. High-resolution structure of the catalytic region of MICAL (molecule interacting with CasL), a multidomain flavoenzyme-signaling molecule. Proc. Natl. Acad. Sci. USA 2005, 102:16836-16841.
17. Ventura A., Pelicci P.G. Semaphorins: green light for redox signaling?. Sci. STKE 2002 2002, PE44.
18. Sun Q., Zhou H., Binmadi N.O., Basile J.R. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J. Biol. Chem. 2009, 284:32066-32074.
19. Cardinali M., Pietraszkiewicz H., Ensley J.F., Robbins K.C. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer 1995, 61:98-103.
20. Siolas D., Lerner C., Burchard J., Ge W., Linsley P.S., Paddison P.J., Hannon G.J., Cleary M.A. Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. 2005, 23:227-231.
21. Hannon G.J., Conklin D.S. RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol. Biol. 2004, 257:255-266.
22. Basile J.R., Holmbeck K., Bugge T.H., Gutkind J.S. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem. 2007, 282:6899-6905.
23. Guedez L., Rivera A.M., Salloum R., Miller M.L., Diegmueller J.J., Bungay P.M., Stetler-Stevenson W.G. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am. J. Pathol. 2003, 162:1431-1439.
24. Sahagun G., Moore S.A., Fabry Z., Schelper R.L., Hart M.N. Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am. J. Pathol. 1989, 134:1227-1232.
25. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem. J. 1987, 19:225-234.
26. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C.J., Sauk J., Sausville E.A., Molinolo A.A., Gutkind J.S. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. 2004, 10:4029-4037.
27. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
28. Aurandt J., Li W., Guan K.L. Semaphorin 4D activates the MAPK pathway downstream of plexin-B1. Biochem. J. 2006, 394:459-464.
29. Hasina R., Whipple M.E., Martin L.E., Kuo W.P., Ohno-Machado L., Lingen M.W. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab. Invest. 2008, 88:342-353.
30. Welsh S.J., Koh M.Y., Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Semin. Oncol. 2006, 33:486-497.
31. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
32. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., Tamagnone L., Comoglio P.M. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 2002, 4:720-724.
33. Ch'ng E., Tomita Y., Zhang B., He J., Hoshida Y., Qiu Y., Morii E., Nakamichi I., Hamada K., Ueda T., Aozasa K. Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 2007, 110:164-172.
34. Valente G., Nicotra G., Arrondini M., Castino R., Capparuccia L., Prat M., Kerim S., Tamagnone L., Isidoro C. Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression. Cell Oncol. 2009, 31:423-436.
35. Rody A., Holtrich U., Gaetje R., Gehrmann M., Engels K., von Minckwitz G., Loibl S., Diallo-Danebrock R., Ruckhaberle E., Metzler D., Ahr A., Solbach C., Karn T., Kaufmann M. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin. Cancer Res. 2007, 13:1115-1122.
36. Rody A., Holtrich U., Pusztai L., Liedtke C., Gaetje R., Ruckhaeberle E., Solbach C., Hanker L., Ahr A., Metzler D., Engels K., Karn T., Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009, 11:R15.
37. McClelland L., Chen Y., Soong J., Kuo I., Scott G. Plexin B1 inhibits integrin-dependent pp125FAK and Rho activity in melanoma. Pigment Cell Melanoma Res. 2011, 24:165-174.
38. Binmadi N.O., Yang Y.H., Zhou H., Proia P., Lin Y.L., Batista De Paula A.M., Sena Guimaraes A.L., Poswar F.O., Sundararajan D., Basile J.R. Plexin-B1 and Semaphorin 4D Cooperate to Promote Perineural Invasion in a RhoA/ROK-Dependent Manner. Am. J. Pathol. 2012, 180:1232-1242.
39. Yang Y.H., Zhou H., Binmadi N.O., Proia P., Basile J.R. Plexin-B1 activates NF-kappaB and IL-8 to promote a pro-angiogenic response in endothelial cells. PLoS One 2011, 6:e25826.
40. Jubb A.M., Strickland L.A., Liu S.D., Mak J., Schmidt M., Koeppen H. Neuropilin-1 expression in cancer and development. J. Pathol. 2012, 226:50-60.
41. Fazzari P., Penachioni J., Gianola S., Rossi F., Eickholt B.J., Maina F., Alexopoulou L., Sottile A., Comoglio P.M., Flavell R.A., Tamagnone L. Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev. Biol. 2007, 7:55.